Guideline development for the management of gout: role of combination therapy with a focus on lesinurad

Gout

2020 American College of Rheumatology Guideline for the Management of Gout

Arthritis Care Res (Hoboken).

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T

doi: 10.1002/acr.24180.

Gout

2020 American College of Rheumatology Guideline for the Management of Gout

Arthritis Rheumatol.

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Edward Sims J, Smith BJ, Wenger NS, Sharon Bae S, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sudhir Kumar Sharma T, Toprover M, Turgunbaev M, Zeng L, Ann Zhang M, Turner AS, Neogi T

doi: 10.1002/art.41247.

T CellsImmune Response

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

J Clin Oncol

Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M

doi: 10.1200/JCO.21.01992

Gout

Lesinurad Combined With Allopurinol: Randomized, Double-Blind, Placebo-Controlled Study in Gout Subjects With Inadequate Response to Standard of Care Allopurinol (A US-based Study)

Arthritis Rheumatol.

Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA

doi: 10.1002/art.39840.

Psoriasis

Joint Aad-Npf Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies

J Am Acad Dermatol.

Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA

doi: 10.1016/j.jaad.2020.02.044.

Rheumatoid Arthritis

Combination therapy with biologic agents in rheumatic diseases: current and future prospects

Ther Adv Musculoskelet Dis.

Inui K, Koike T

doi: 10.1177/

COMMENTED

Gout

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout

Rheumatology (Oxford).

Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, Jalal D, Pillinger M, White WB

doi: 10.1093/rheumatology/key245.

Immunodeficiency

Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency

J Allergy Clin Immunol.

Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincoe A, Gaspar HB, Notarangelo LD, Grunebaum E

doi: 10.1016/j.jaci.2018.08.024.

Gout

Gout: state of the art after a decade of developments

Rheumatology (Oxford).

Pascart T, Lioté F

doi: 10.1093/rheumatology/key002.

Related content

2020 American College of Rheumatology Guideline for the Management of Gout

2020 American College of Rheumatology Guideline for the Management of Gout

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Lesinurad Combined With Allopurinol: Randomized, Double-Blind, Placebo-Controlled Study in Gout Subjects With Inadequate Response to Standard of Care Allopurinol (A US-based Study)

Joint Aad-Npf Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies

Combination therapy with biologic agents in rheumatic diseases: current and future prospects

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout

Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency

Gout: state of the art after a decade of developments